Literature DB >> 28528156

Prognostic Impact of Low-Flow Severe Aortic Stenosis in Small-Body Patients Undergoing TAVR: The OCEAN-TAVI Registry.

Akihisa Kataoka1, Yusuke Watanabe2, Ken Kozuma3, Yugo Nara3, Fukuko Nagura3, Hideyuki Kawashima3, Hirofumi Hioki3, Makoto Nakashima3, Masanori Yamamoto2, Kensuke Takagi4, Motoharu Araki5, Norio Tada6, Shinichi Shirai7, Futoshi Yamanaka8, Kentaro Hayashida9.   

Abstract

OBJECTIVES: This study aimed to analyze the prognostic impact of low-flow (LF) severe aortic stenosis in small-body patients undergoing transcatheter aortic valve replacement (TAVR).
BACKGROUND: Western literature demonstrates a poor prognosis with paradoxical LF and low-flow low-gradient (LF-LG) severe aortic stenosis (AS), as defined by stroke volume index (SVi) <35 ml/m2 and mean pressure gradient <40 mm Hg with preserved left ventricular ejection fraction (LVEF). However, this poor prognosis is contested in Japan owing to the smaller body size of Japanese patients relative to that of Western patients. Additionally, there are no reports of the prognostic implication of paradoxical LF or LF-LG severe AS in small-body patients undergoing TAVR.
METHODS: This was a retrospective analysis of 723 consecutive Japanese patients (median age 85 years; 32.6% male; median body surface area 1.4 m2) who underwent TAVR for severe AS at 9 sites in Japan. The primary and secondary endpoints were cumulative all-cause and cardiovascular mortality after TAVR, respectively.
RESULTS: Ninety-seven (13.4%) patients had paradoxical LF severe AS whereas 38 (5.3%) had paradoxical LF-LG with severe AS. PLF was associated with a significant increase in all-cause (hazard ratio [HR]: 3.00; 95% confidence interval [CI]: 1.34 to 6.72; p < 0.001) and cardiovascular mortality (HR: 5.58; 95% CI: 1.19 to 26.2; p < 0.01), as compared with patients' normal flow and preserved LVEF. PLF-LG was associated with a significant increase in all-cause mortality (HR: 3.76; 95% CI: 1.09 to 13.73; p < 0.01), as compared with normal flow high gradient with preserved LVEF. SVi was an independent predictor of cardiovascular mortality on multivariate analysis after adjustments for age, sex, clinically relevant variables, and other echocardiographic parameters (HR: 1.96; 95% CI: 1.19 to 3.23; p < 0.01).
CONCLUSIONS: Among Japanese small-body patients with severe AS, both paradoxical LF and LF-LG severe AS were associated with poor outcomes following TAVR. SVi was an independent predictor of cardiovascular mortality after TAVR. (Optimised Transcatheter Valvular Intervention registry [OCEAN-TAVI]; UMIN000020423).
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  paradoxical low-flow low-gradient severe aortic stenosis; paradoxical low-flow severe aortic stenosis; small body; stroke volume index; transcatheter aortic valve replacement

Mesh:

Year:  2017        PMID: 28528156     DOI: 10.1016/j.jcmg.2016.12.028

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  8 in total

1.  Comparison of midterm outcomes of transcatheter aortic valve implantation in patients with and without previous coronary artery bypass grafting.

Authors:  Hideyuki Kawashima; Yusuke Watanabe; Ken Kozuma; Akihisa Kataoka; Makoto Nakashima; Hirofumi Hioki; Fukuko Nagura; Yugo Nara; Shinichi Shirai; Norio Tada; Motoharu Araki; Toru Naganuma; Futoshi Yamanaka; Hiroshi Ueno; Minoru Tabata; Kazuki Mizutani; Akihiro Higashimori; Kensuke Takagi; Masanori Yamamoto; Kentaro Hayashida
Journal:  Heart Vessels       Date:  2018-04-21       Impact factor: 2.037

2.  Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow and normal-flow severe aortic stenosis.

Authors:  Miho Mitsui; Akihisa Kataoka; Yugo Nara; Fukuko Nagura; Hideyuki Kawashima; Hirofumi Hioki; Makoto Nakashima; Yusuke Watanabe; Naoyuki Yokoyama; Ken Kozuma
Journal:  Heart Vessels       Date:  2019-04-16       Impact factor: 2.037

Review 3.  The Pivotal Role of Imaging in TAVR Procedures.

Authors:  Caroline Bleakley; Mark J Monaghan
Journal:  Curr Cardiol Rep       Date:  2018-02-12       Impact factor: 2.931

4.  Paradoxical low-flow aortic stenosis - baseline characteristics, impact on mortality.

Authors:  Karol Zbroński; Zenon Huczek; Monika Gawalko; Agata Ćwiek; Bartosz Rymuza; Kajetan Grodecki; Piotr Scisło; Radosław Wilimski; Janusz Kochman; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-04-04       Impact factor: 1.426

5.  Prognostic impact of postprocedure stroke volume in patients with low-gradient aortic stenosis.

Authors:  Yugo Nara; Akihisa Kataoka; Yusuke Watanabe; Nakashima Makoto; Hirofumi Hioki; Hideyuki Kawashima; Nagura Fukuko; Ken Kozuma; Shinichi Shirai; Norio Tada; Motoharu Araki; Toru Naganuma; Futoshi Yamanaka; Hiroshi Ueno; Minoru Tabata; Kazuki Mizutani; Akihiro Higashimori; Kensuke Takagi; Masanori Yamamoto; Kentaro Hayashida
Journal:  Open Heart       Date:  2019-05-24

6.  Risk prediction in patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction undergoing TAVI.

Authors:  Sebastian Ludwig; Alina Goßling; Moritz Seiffert; Dirk Westermann; Jan-Malte Sinning; Atsushi Sugiura; Matti Adam; Victor Mauri; Derk Frank; Hatim Seoudy; Tanja Rudolph; Max Potratz; Lenard Conradi; Niklas Schofer
Journal:  Open Heart       Date:  2022-01

7.  Predictors and clinical outcomes of poor symptomatic improvement after transcatheter aortic valve replacement.

Authors:  Nobuhiro Yoshijima; Tetsuya Saito; Taku Inohara; Atsushi Anzai; Hikaru Tsuruta; Hideyuki Shimizu; Keiichi Fukuda; Toru Naganuma; Kazuki Mizutani; Masahiro Yamawaki; Norio Tada; Futoshi Yamanaka; Shinichi Shirai; Minoru Tabata; Hiroshi Ueno; Kensuke Takagi; Yusuke Watanabe; Masanori Yamamoto; Kentaro Hayashida
Journal:  Open Heart       Date:  2021-11

8.  Statin therapy for patients with aortic stenosis who underwent transcatheter aortic valve implantation: a report from a Japanese multicentre registry.

Authors:  Fumiaki Yashima; Masahiko Hara; Taku Inohara; Masahiro Jinzaki; Hideyuki Shimizu; Keiichi Fukuda; Makoto Tanaka; Masanori Yamamoto; Yusuke Watanabe; Toru Naganuma; Shinichi Shirai; Masahiro Yamawaki; Norio Tada; Futoshi Yamanaka; Kazuki Mizutani; Hiroshi Ueno; Minoru Tabata; Kensuke Takagi; Kentaro Hayashida
Journal:  BMJ Open       Date:  2021-06-11       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.